[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617815":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":69,"collaborators":73,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin 10 mg daily","ACTIVE_COMPARATOR","Subjects will receive masked dapagliflozin 10 mg daily for 12 weeks",[13],"Drug: Dapagliflozin (10Mg Tab) along with standard medical therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Matching placebo pill daily","PLACEBO_COMPARATOR","Subjects will receive a matching placebo pill to take daily for 12 weeks",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dapagliflozin (10Mg Tab) along with standard medical therapy","Pilot and feasibility of adding dapagliflozin to standard medical therapy in active lupus nephritis (LN)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Matching placebo daily with standard of care",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Karen H Costenbader, MD, MPH","CONTACT","(617) 525-8785","kcostenbader@bwh.harvard.edu",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"April M Jorge, MD","617-643-9624","amjorge@mgh.harvard.edu",[42,59],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Massachusetts General Hospital","RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-71.05977,42.35843,{"lat":54,"lon":53},[57],{"name":58,"role":34,"phone":39,"phoneExt":26,"email":40},"April M. Jorge, MD",{"facility":5,"status":44,"city":45,"state":46,"zip":60,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"02115",{"type":51,"coordinates":62},[53,54],{"lat":54,"lon":53},[65],{"name":66,"role":34,"phone":67,"phoneExt":26,"email":68},"Karen H. Costenbader, MD, MPH","617-732-6088","KCostenbader@bwh.harvard.edu",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Karen H. Costenbader","Associate Physician, Rheumatologist",[74],{"name":43,"class":6},"100617815","phase-4-dapagliflozin-in-active-lupus-nephritis-100617815",false,"NCT07323524","Dapagliflozin in Active Lupus Nephritis","Sodium-Glucose Co-Transporter-2 Inhibitors in Lupus Nephritis","Dapa-Active LN","Inclusion Criteria:\n\n* • Age 18-70 years, fulfilling 2012 SLICC or 2019 ACR\u002FEULAR criteria for SLE, with biopsy-proven class III, IV and\u002For V LN\n\n  * Active (new or relapsing) LN within the prior six months, with at least one of the following:\n\n    * Kidney biopsy with activity index \\>2 and\u002For\n    * Active urinary sediment (\\>5 RBCs, \\>5 WBCs, or cellular casts)\n  * Receiving standard-of-care immunosuppression regimen for active LN, including mycophenolate, cyclophosphamide, belimumab, azathioprine, a calcineurin inhibitor, and\u002For B cell depleting therapies\n  * Recent or ongoing glucocorticoids use for active LN within the past 6 months\n  * Receiving standard-of-care antimalarial therapy and RAAS blockade, unless contraindicated\n  * Estimated ≥0.5 g\u002Fg 24 hr proteinuria or ≥0.3 mg\u002Fg 24 hr microalbuminuria at enrollment (on first morning urine)\n  * Ability to given informed consent\n\nExclusion Criteria:\n\n* GFR \\\u003C 25 ml\u002Fmin\u002F1.73m2\n\n  * Acute kidney injury at study enrollment (\\>50 percent rise in creatinine within 90 days)\n  * Type I diabetes, underweight (BMI \\\u003C18.5), active malignancy, active infection, or recurrent genitourinary infections\n  * For females: pregnancy, or desiring of pregnancy and not using contraception, or unable to use contraception\n  * Current use of \\>1mg\u002Fkg\u002Fday prednisone equivalent\n  * Current or prior use of SGLT2 inhibitors or GLP-1 receptor agonists","ALL","18 Years","70 Years",{"count":87,"type":88},33,"ESTIMATED","INTERVENTIONAL",[91],"PHASE4","Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials.",[94],"Lupus Nephritis (LN)",[96,97,98,99,100],"dapagliflozin","SGLT2 inhibitor","safety","feasibility","pilot trial","2026-05-21",{"date":103,"type":104},"2026-05-26","ACTUAL",{"date":106,"type":104},"2026-05-19",{"date":108,"type":88},"2030-01",{"name":5,"class":6},2]